ACell Nabs FDA Clearance for MicroMatrix
ACell has received FDA clearance for its MicroMatrix device to be used in conjunction with with Cytal Wound Matrix and Cytal Burn Matrix devices for wound management.
The MicroMatrix aids coverage of irregular wound beds, and Cytal Wound and Cytal Burn facilitate cell infiltration and host tissue deposition.
The clearance also allows the device to be sterilized in saline before surgery to promote ease and adherence.
This is ACell’s third FDA clearance over the past year, according to company President and CEO Patrick McBrayer. — Anisa Jibrell